Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

February 6, 2022 updated by: Shanghai Junshi Bioscience Co., Ltd.

A Randomized, Double-blind, Placebo-controlled, Phase II, Multicenter Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetics of Subcutaneous JS005 in Chinese Adults With Active Non-radiographic Axial Spondyloarthritis

The purpose of this study is to evaluate preliminary efficacy, safety pharmacokinetic (PK) characteristics, pharmacodynamics (PD) haracteristics and immunogenicity of JS005 at different doses in Chinese patients with active non-radiographic axial spondyloarthritis(nr-axSpA). Treatment difference of JS005 150mg,300mg,450mg vs. placebo in Chinese nr-axSpA patients in terms of ASAS 40 response rate at Week 16 as well as safety profile will be provided by the study .

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a randomized, double-blind, placebo-controlled study. Approximately 120 patients who meet the eligibility criteria will be randomized to one of three treatment cohorts (JS005 150 mg, 300 mg, 450mg in a ratio of 1:1:1),then using secondary randomization method, 40 patients in each group will be randomized in a 3: 1 ratio to receive investigational product or placebo.

  1. JS005 150mg Cohort: JS005 150 mg or placebo treatment(JS005:Placrbo=3:1) s.c. prefilled syringe (PFS) on Week 0, 1, 2, 3, 4,8 and 12
  2. JS005 300mg Cohort: JS005 300 mg or placebo treatment(JS005:Placrbo=3:1) s.c. PFS on Week0, 1, 2 ,3, 4,8,and 12 3 .JS005 450mg Cohort: JS005 450 mg or placebo treatment(JS005:Placrbo=3:1) s.c. PFS on Week0, 1, 2 ,3, 4,8,and 12 Based on the clinical judgment of disease activity by the investigator and the patient, background medications, such as NSAIDs and DMARDs, may have been modified or added to treat signs and symptoms of nr-axSpA from Week 16 on.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • China
    • Anhui
      • Hefei, Anhui, China, 230001
        • Not yet recruiting
        • Anhui Provincial Hospital
        • Contact:
        • Principal Investigator:
          • Xiaomei Li, M.D.
    • Fujian
      • Xiamen, Fujian, China, 410011
        • Not yet recruiting
        • The First Affiliated Hospital of Xiamen University
        • Contact:
        • Principal Investigator:
          • Guixiu Shi, M.D.
    • Guangdong
      • Guangzhou, Guangdong, China, 510515
        • Recruiting
        • Nanfang Hospital of Nanfang Medical University
        • Contact:
        • Principal Investigator:
          • Min Yang, M.D.
      • Guangzhou, Guangdong, China, 510120
        • Not yet recruiting
        • Sun Yat-sen Memorial Sun Yat-sen University
        • Contact:
        • Principal Investigator:
          • Donghui Zhen, M.D.
      • Shantou, Guangdong, China, 515041
        • Not yet recruiting
        • Shantou University Medical Collge No.1 Affiliated Hospital
        • Contact:
        • Principal Investigator:
          • Zhiyi Hou, M.D.
      • Shenzhen, Guangdong, China, 518001
        • Not yet recruiting
        • Shenzhen People's Hospital
        • Principal Investigator:
          • Dongzhou LIU, M.D.
        • Contact:
      • Shenzhen, Guangdong, China, 518036
        • Not yet recruiting
        • Pking University Shenzhen Hospital
        • Contact:
        • Principal Investigator:
          • Qingwen Wang, M.D.
    • Henan
      • Zhengzhou, Henan, China, 361001
        • Not yet recruiting
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
        • Principal Investigator:
          • Shengyun Liu, M.D.
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Not yet recruiting
        • Tongji Hospital,Tongji Medical college of Hust
        • Contact:
        • Principal Investigator:
          • Linli Dong, M.D.
    • Hunan
      • Changsha, Hunan, China, 361001
        • Not yet recruiting
        • The third xiangya hospital of Central South University
        • Contact:
        • Principal Investigator:
          • Jian Sun, M.D.
      • Changsha, Hunan, China, 410013
        • Not yet recruiting
        • The Second Xiangya Hospital Of Central South University
        • Contact:
        • Principal Investigator:
          • Xi Xie, M.D.
    • Inner Mongolia
      • Hohhot, Inner Mongolia, China, 100000
        • Not yet recruiting
        • The Affilated Hospital of Inner Mongdlia Medical University
        • Principal Investigator:
          • Hongbin LI, M.D.
        • Contact:
    • Jilin
      • Changchun, Jilin, China, 130021
        • Not yet recruiting
        • The First Hospital of Jilin University
        • Contact:
        • Principal Investigator:
          • Zhenyu Jia, M.D.
    • Liaoning
      • Dalian, Liaoning, China, 116023
        • Not yet recruiting
        • The Second Affiliated Hospital of Dalian Medical University
        • Principal Investigator:
          • Xiaodan Kong, M.D.
        • Contact:
      • Shenyang, Liaoning, China, 110004
        • Not yet recruiting
        • Shengjing Hospital of China Medical University
        • Contact:
        • Principal Investigator:
          • Xiaofei Wang, M.D.
      • Shenyang, Liaoning, China, 110001
        • Not yet recruiting
        • The First Affiliated Hospital of China Medical University
        • Contact:
        • Principal Investigator:
          • Pinting Yang, M.D.
    • Shandong
      • Jinan, Shandong, China, 030001
        • Not yet recruiting
        • Qilu Hospital of Shandong University
        • Contact:
        • Principal Investigator:
          • Huaxiang Liu, M.D.
    • Shanghai
      • Shanghai, Shanghai, China, 200003
        • Not yet recruiting
        • Shanghai Changzheng Hospital
        • Contact:
        • Principal Investigator:
          • Huji Xu, M.D.
    • Shanxi
      • Taiyuan, Shanxi, China, 650032
        • Not yet recruiting
        • First Affiliated Hospital of Shanxi Medical University
        • Contact:
        • Principal Investigator:
          • Zili Fu, M.D.
    • Sichuan
      • Chengdu, Sichuan, China, 600041
        • Not yet recruiting
        • West China Hospital, Sichuan University
        • Contact:
        • Principal Investigator:
          • Yi liu, M.D.
      • Nanchong, Sichuan, China, 637000
        • Not yet recruiting
        • North Sichuan Medical College Affiliated Hospital
        • Contact:
        • Principal Investigator:
          • Guohua Yuan, M.D.
    • Tianjin
      • Tianjin, Tianjin, China, 300041
        • Not yet recruiting
        • Tianjin Medical University General Hospital
        • Principal Investigator:
          • Wei Wei, M.D.
        • Contact:
    • Xinjiang
      • Urumqi, Xinjiang, China, 8300001
        • Not yet recruiting
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Contact:
        • Principal Investigator:
          • Lijun Wu, M.D.
    • Yunnan
      • Kunming, Yunnan, China, 250063
        • Not yet recruiting
        • First Affiliated Hospital of Kunming Medical University
        • Principal Investigator:
          • Jian Xu, M.D.
        • Contact:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 450052
        • Not yet recruiting
        • The Second Affiliated Hospital of Zhejiang University,School of Medicine
        • Contact:
        • Principal Investigator:
          • Huaxiang Wu, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients who do not meet the modified New York criteria for AS in 1984; Meet the 2009 axSpA classification criteria recommended by International Assessment Society of Axial Spondyloarthritis (ASAS): inflammatory back pain for at least 3 months; Age of onset < 45 years; Sacroiliitis on MRI with≥ 1 axial spondyloarthritis features or HLA-B27 positive with ≥ 2 SpA features (MRI and X-ray of sacroiliac joint as confirmed by central readers).
  2. Objective signs of inflammation at screening: active inflammation of the sacroiliac joints on MRI and/or high sensitivity C-reactive protein (hsCRP) > upper limit of normal without other diagnoses to explain the MRI results or elevated hsCRP.
  3. Active axSpA at screening and baseline: assessed by total Bath ankylosing spondylitis disease activity index (BASDAI) ≥ 4 (0-10 scale) and spinal pain ≥ 4 (according to the 0-10 NRS scale, BASDAI question #2).
  4. Voluntarily participate in this clinical trial and sign the informed consent form.
  5. Male or female aged between 18 and 65 years (both inclusive) at the time of signing informed consent. Female subjects of childbearing age are required to have a confirmed negative result of urine and/or serum pregnancy test performed within 3 days before randomization and agree to use reliable contraceptive measures during the study; Male subjects and their female partners of childbearing age must agree to use reliable contraception during the study.
  6. Patients meet at least one of the following: 1) have an inadequate or ineffective response to NSAIDs, 2) have been intolerant to at least one dose of NSAIDs, 3) have contraindications to NSAIDs therapy. Inadequate or ineffective response to NSAIDs is defined as no remission after continuous treatment with standard doses of at least 2 NSAIDs for a total of no less than 4 weeks and no less than 2 weeks for each NSAID.
  7. Patients regularly taking NSAIDs as part of their AS therapy are required to maintain a stable dose for at least 2 weeks prior to randomization.
  8. Patients using tumor necrosis factor α (TNFα) inhibitors must have experienced an inadequate response to the standard treatment dose for at least 3 months, or have been intolerant to TNFα inhibitors.

Exclusion Criteria:

  1. Unable or unwilling to undergo MRI.
  2. Previous exposure to JS005 or any other biologic drug directly targeting IL-17 or IL-17 receptor.
  3. Have taken high potency analgesics (e.g., opiates of methadone, hydromorphone, morphine) within 2 weeks prior to randomization.
  4. Previous treatment with any intra-articular injection (e.g., glucocorticoids) within 4 weeks prior to randomization.
  5. Previous treatment with any biological immunomodulating agents other than the TNFα inhibitors.
  6. Treatment with JAK inhibitor agents within 8 weeks prior to randomization and unwilling to discontinue during the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: JS005 150 mg
30 patients will be enrolled in this arm.
Biological: JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Other Names:
  • Recombinant humanized anti-IL-17A monoclonal antibody injection
Placebo Comparator: Placebo 150 mg
10 patients will be enrolled in this arm.
Biological: Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Experimental: JS005 300 mg
30 patients will be enrolled in this arm.
Biological: JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Other Names:
  • Recombinant humanized anti-IL-17A monoclonal antibody injection
Placebo Comparator: Placebo 300 mg
10 patients will be enrolled in this arm.
Biological: Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Experimental: JS005 450 mg
30 patients will be enrolled in this arm.
Biological: JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Other Names:
  • Recombinant humanized anti-IL-17A monoclonal antibody injection
Placebo Comparator: Placebo 450
10 patients will be enrolled in this arm.
Biological: Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The proportion of nr-axSpA patients meeting the Assessment of Spondylo Arthritis international Society (ASAS) 40 response criteria
Time Frame: From week 0 to week 16
at the end of treatment Week 16 .
From week 0 to week 16

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
ASAS20 response criteria
Time Frame: From week 0 to week 16
The proportion of patients meeting the ASAS20 response criteria at the end of treatment Week 16
From week 0 to week 16
ASAS 5/6 response criteria
Time Frame: From week 0 to week 16
The proportion of patients meeting the ASAS 5/6 response criteria at the end of treatment Week 16;
From week 0 to week 16
High-sensitivity C-reactive protein (hsCRP)
Time Frame: From week 0 to week 16
The change from baseline in high-sensitivity C-reactive protein (hsCRP) at the end of treatment Week 16
From week 0 to week 16
The inflammation score of the sacroiliac joint
Time Frame: From week 0 to week 16
The change from baseline in the inflammation score of the sacroiliac joint by MRI at the end of treatment Week 16
From week 0 to week 16
Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP)
Time Frame: From week 0 to week 16
The change from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) at the end of treatment Week 16;
From week 0 to week 16
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Time Frame: From week 0 to week 16
The change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at the end of treatment Week 16
From week 0 to week 16
Bath Ankylosing Spondylitis Functional Index (BASFI)
Time Frame: From week 0 to week 16
The change from baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at the end of treatment Week 16
From week 0 to week 16
Bath Ankylosing Spondylitis Disease Metrology Index (BASMI)
Time Frame: From week 0 to week 16
The change from baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at the end of treatment Week 16
From week 0 to week 16
Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Time Frame: From week 0 to week 16
The change from baseline in Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) at the end of treatment Week 16
From week 0 to week 16
The patient's global assessment of disease activity
Time Frame: From week 0 to week 16
Numeric Rating Scale (NRS, ranging from 0 not active to 10 very active) will be used to evaluate the patient's global assessment of disease activity. Patient will be asked by one question: How active was your spondylitis on average during the last week？
From week 0 to week 16
The patient's assessment of inflammatory back pain intensity
Time Frame: From week 0 to week 16
NRS(ranging from 0 no pain to 10 most severe pain) will be used to assess the patient's inflammatory back pain intensity. The assessment is based on two questions: "Based on your assessment, please indicate How much pain of your spine due to AS do you have ?" and "Based on your assessment, please specify How much pain of your spine due to AS do you have at night?" When responding, the subject is to consider the average amount of pain in the last week.
From week 0 to week 16
ASAS partial remission criteria
Time Frame: From week 0 to week 16
The proportion of patients meeting ASAS partial remission criteria at the end of treatment Week 16
From week 0 to week 16

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Pharmacokinetic endpoint
Time Frame: From Baseline to week 24,Total 24 weeks
• Population pharmacokinetic analysis of plasma concentrations will be performed to explore the exposure of JS005 in patients and the influencing factors of exposure
From Baseline to week 24,Total 24 weeks
Pharmacodynamic endpoint
Time Frame: From Baseline to week 24,Total 24 weeks
• Concentrations and the changes of free and/or total IL-17 in serum before and after administration.
From Baseline to week 24,Total 24 weeks
Immunogenicity endpoint
Time Frame: From Baseline to week 24,Total 24 weeks
• Anti-drug antibody (ADA), for the ADA positive samples, it is necessary to test the titer and determine whether it is a neutralizing antibody (Nab).
From Baseline to week 24,Total 24 weeks
Safety evaluation
Time Frame: From V1 to V12, Total 36 Weeks
Safety evaluation will be documented as numbers of adverse event(AE).
From V1 to V12, Total 36 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Shanghai Junshi Bioscience Co., Ltd.

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Sponsor GmbH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 26, 2022

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2023

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 10, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 30, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 6, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 16, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 16, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 6, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • JS005-004-II-nr-axSpA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-radiographic Axial Spondyloarthritis

Clinical Trials on JS005

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings